From uncovering why young adults face rising cancer rates to pioneering vaccines and new therapies, MSK’s latest research is shaping the future of cancer care in the Middle East and worldwide.
DOHA, DUBAI, RIYADH. September 24, 2025. On World Cancer Research Day, Memorial Sloan Kettering Cancer Center (MSK) highlights pioneering research that is improving treatment options, expanding access to precision care, and offering hope to patients across the Middle East.
Key breakthroughs include:
- Promising leads for the mystery of increasing rates of cancer in young adults. Serious cancers, including colorectal, breast, prostate, uterine, stomach, and pancreatic cancers, are increasingly diagnosed in people under 50. Early findings point to a mix of influences, from changes in the gut microbiome and environmental exposures to lifestyle and reproductive factors. MSK’s Young Adult Cancer Program combines advanced genomic testing with personalized support to better understand these trends and improve prevention, early detection, and care for younger patients.
- KRAS-targeting vaccine advances treatment options. MSK has developed an “off-the-shelf” vaccine for pancreatic and colorectal cancers driven by KRAS gene mutations, a common driver of tumor growth. Unlike personalized vaccines, it can be mass-produced and stored for immediate use. Early results show that the vaccine triggers the immune system and helps control tumor growth in some patients, potentially providing a faster and more widely accessible treatment option.
- Some women may safely skip additional radiation after mastectomy. For women whose breast cancer initially spread to lymph nodes but clears after pre-surgery (neoadjuvant) chemotherapy, extra radiation to the nodes may not be needed. A study found that skipping this radiation did not increase the risk of cancer returning, helping avoid unnecessary treatment and long-term side effects.
- New CAR T cells attack aggressive blood cancer in pilot study. MSK tested a novel CAR T cell therapy in patients with advanced acute myeloid leukemia (AML). In the first trial of its kind, the engineered cells targeted leukemia effectively without major side effects, opening new possibilities for hard-to-treat blood cancers.
- Pembrolizumab boosts survival in head and neck cancer. Adding pembrolizumab before and after standard therapy significantly extends the time patients remain cancer-free in locally advanced head and neck cancer – the first major positive result in two decades.
- MSK-led research drives 11 FDA approvals. MSK-led clinical trials contributed to 11 FDA approvals in 2024, covering brain, lung, breast, thyroid, and colorectal cancers. These approvals include new drug uses, targeted therapies, and engineered cell therapies, expanding treatment options for patients worldwide.
- Immunotherapy combination improves survival in advanced liver cancer. The global HIMALAYA study, with key involvement from MSK, showed that an immunotherapy combination reduced the risk of death by 22% compared with standard treatment in patients with advanced liver cancer. The trial, which enrolled over a thousand patients worldwide, established this regimen as a new first-line option for liver cancers that cannot be removed surgically.
“World Cancer Research Day reminds us that every discovery, from lab insights to new treatment strategies, has the potential to save lives,” says Dr. Ghassan Abou-Alfa, Gastrointestinal Medical Oncologist at MSK. “Our goal is to ensure these advances reach patients worldwide, including the Middle East, Africa, Eurasia, Asia, and the Americas, and directly improve outcomes. We aim to lead the way in innovations that treat, and ultimately prevent, cancer in the region.”
With more than 100 research laboratories, MSK maintains one of the world’s most dynamic programs of cancer research. The Sloan Kettering Institute (SKI), MSK’s basic research arm, is dedicated to understanding the biology of cancer and collaborates closely with MSK physician-scientists to accelerate discoveries from lab to patient. MSK also runs one of the world’s largest clinical trial programs.
MSK continues to expand access to world-class care for patients from across the globe, including the Middle East, through innovative clinical trials, innovative vaccines, and transformative therapies, reflecting its mission to lead in cancer research, education, and clinical excellence.
###
About Memorial Sloan Kettering Cancer Center (MSK)
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 35 years. http://www.mskcc.org.